Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 5.53 is 52% below its 5-year average of 11.60, near the low end of its 5-year range (4.42–29.60).
As of the fiscal period ended Tuesday, June 30, 2026. 0.06% below its 12-month average of 5.53.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.53.
CURRENT RATIO
5.53
CURRENT RATIO AVG TTM
5.53
CURRENT RATIO AVG 3Y
10.86
CURRENT RATIO AVG 5Y
11.60
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-0.06%
CURRENT VS 3Y AVG
-49.11%
CURRENT VS 5Y AVG
-52.32%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+47.43%
vs the sector median at left
Market Cap
$657.89M
Current Ratio
1.36
TTM Avg
1.59
3Y Avg
1.59
5Y Avg
1.59
Market Cap
$656.59M
Current Ratio
8.03
TTM Avg
12.16
3Y Avg
13.50
5Y Avg
14.42
Market Cap
$681.27M
Current Ratio
13.82
TTM Avg
5.67
3Y Avg
7.51
5Y Avg
7.66
Market Cap
$638.20M
Current Ratio
16.82
TTM Avg
9.46
3Y Avg
14.12
5Y Avg
14.05
Market Cap
$685.49M
Current Ratio
14.20
TTM Avg
2.62
3Y Avg
2.46
5Y Avg
2.12
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Annexon, Inc. (ANNX) | $660.29M | 5.53 | 5.53 | 10.86 | 11.60 |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | 1.36 | 1.59 | 1.59 | 1.59 |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | 8.03 | 12.16 | 13.50 | 14.42 |
| Helus Pharma Inc. (HELP)vs › | $666.95M | 10.97 | 8.63 | 10.75 | 10.66 |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 5.33 | 4.27 | 3.79 | 3.57 |
| Verastem, Inc. (VSTM)vs › | $681.02M | 2.25 | 3.08 | 3.98 | 5.01 |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | 13.82 | 5.67 | 7.51 | 7.66 |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | 16.82 | 9.46 | 14.12 | 14.05 |
| Anteris Technologies Global Corp. (AVR)vs › | $685.49M | 14.20 | 2.62 | 2.46 | 2.12 |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 5.17 | 4.10 | 4.28 | 7.57 |
Current Ratio
5.53
Quick Ratio
5.53
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 5.53 |
| 2026-03-31 | 6.35 |
| 2025-12-31 | 5.68 |
| 2025-09-30 | 4.42 |
| 2025-06-30 | 5.67 |
| 2025-03-31 | 7.99 |
| 2024-12-31 | 10.37 |
| 2024-09-30 | 17.18 |
| 2024-06-30 | 21.81 |
| 2024-03-31 | 20.62 |
| 2023-12-31 | 14.72 |
| 2023-09-30 | 9.85 |
| 2023-06-30 | 11.04 |
| 2023-03-31 | 10.14 |
| 2022-12-31 | 11.10 |
| 2022-09-30 | 13.59 |
| 2022-06-30 | 8.95 |
| 2022-03-31 | 12.39 |
| 2021-12-31 | 11.39 |
| 2021-09-30 | 23.11 |
| 2021-06-30 | 29.60 |
| 2021-03-31 | 30.90 |
| 2020-12-31 | 33.33 |
| 2020-09-30 | 41.56 |
| 2020-06-30 | 9.93 |
| 2020-03-31 | 5.45 |
| 2019-12-31 | 9.21 |
| 2019-09-30 | 10.68 |
| 2019-06-30 | 8.58 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | 13.74 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
